Skip to main content
JEIL PHARMACEUTICAL CO.,LTD logo

JEIL PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 271980 ISIN · KR7271980005 KO Manufacturing
Open in API
Filings indexed 135 across all filing types
Latest filing 2019-03-06 AGM Information
Country KR South Korea
Listing KO 271980

About JEIL PHARMACEUTICAL CO.,LTD

https://www.jeilpharm.co.kr/english/

JEIL PHARMACEUTICAL CO.,LTD. is a company engaged in the development, manufacturing, and distribution of pharmaceutical products. Its portfolio includes both finished drug products and Active Pharmaceutical Ingredients (APIs). The company produces a diverse range of dosage forms, such as solid medicines (tablets and capsules), patches, and injections, with a strategic focus on becoming a leading manufacturer of injection-based medicines. Committed to developing high-value products, the company operates KGMP-certified manufacturing facilities. Research and development activities are central to its operations, driven by its dedicated R&D center.

Recent filings

Filing Released Lang Actions
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Jeil Pharmaceutical Co., Ltd. It contains the meeting agenda, details on board activities, financial statements (balance sheet, income statement, etc.), and management information. This type of document is standard for providing shareholders with the necessary information to vote at an upcoming AGM. In the context of financial filings, this is classified as a Proxy Solicitation & Information Statement (PSI) as it serves to inform shareholders and solicit their votes for the meeting.
2019-03-06 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of a General Meeting (주주총회소집결의) issued by Jeil Pharmaceutical. It outlines the date, location, and agenda items (such as financial statement approval, board appointments, and remuneration limits) for the upcoming Annual General Meeting. This document serves as the official proxy solicitation and meeting notice provided to shareholders, which falls under the Proxy Solicitation & Information Statement category.
2019-02-26 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Jeil Pharmaceutical regarding the decision to pay cash dividends. It specifies the dividend amount per share, the total dividend amount, the record date, and the date of the upcoming general meeting of shareholders to approve the dividend. This aligns perfectly with the definition of a 'Notice of Dividend Amount' (DIV).
2019-02-26 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. This document tracks changes in significant share ownership (crossing thresholds or changes in major shareholding status). Based on the provided filing definitions, this corresponds to the 'Major Shareholding Notification' category.
2019-02-12 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Management Reports Classification · 95% confidence The document is a regulatory filing from a Korean company (Jeil Pharmaceutical) announcing a significant change in revenue or profit structure (30% or more). This is a standard regulatory disclosure requirement in the Korean market (DART system) for preliminary earnings results before the final audit report is issued. Since it provides key financial highlights and preliminary earnings data, it falls under the Earnings Release (ER) category.
2019-02-07 Korean
최대주주등소유주식변동신고서(최대주주변경시)
Regulatory Filings Classification · 95% confidence The document is a 'Report of Change in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) for Jeil Pharmaceutical. It details specific changes in share ownership, including the names of shareholders, the number of shares held before and after the change, and the reasons for the change (e.g., public tender offer). This type of filing is a regulatory requirement for disclosing significant changes in ownership structure and does not fit into categories like 10-K, IR, or M&A. It is best classified as a Regulatory Filing (RNS) as it is a standard disclosure document for major shareholding changes in the Korean market.
2018-11-19 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.